Arbitrum (ARB) is currently trading at $0.5156, having recorded a gain of 3.57% in the past 24 hours. However, volumes in trades have declined, coming in 42.38% lower to $278.51 million. For the past seven days, ARB has recorded losses by 10.79%, exchanging hands around the average price of $0.5163 per week. Market commentators are […]Arbitrum (ARB) is currently trading at $0.5156, having recorded a gain of 3.57% in the past 24 hours. However, volumes in trades have declined, coming in 42.38% lower to $278.51 million. For the past seven days, ARB has recorded losses by 10.79%, exchanging hands around the average price of $0.5163 per week. Market commentators are […]

Arbitrum (ARB) Price Forecast: Will ARB Hit $2.40 Again or Struggle Below $0.50?

Arbitrum
  • Arbitrum (ARB) shows short-term gains despite a steep weekly decline.
  • Analysts predict a possible surge toward the $1.22 mark if momentum holds.
  • Forecasts for 2025 remain divided, ranging from $0.38 to $2.40.

Arbitrum (ARB) is currently trading at $0.5156, having recorded a gain of 3.57% in the past 24 hours. However, volumes in trades have declined, coming in 42.38% lower to $278.51 million. For the past seven days, ARB has recorded losses by 10.79%, exchanging hands around the average price of $0.5163 per week.

image 818Source: CoinMarketCap

Market commentators are buoyant in their assessment that the asset’s short-term trend is influenced by speculative interest as much as technical strength. Despite the mixed short-term prospects, the question remains as to whether ARB can mount a significant return into 2025.

ARB Market Support Strengthens Despite Risks

Crypto analyst Thomas Reid noted the recent consolidation in the $0.49 region for ARB as being representative of underlying support. The current “strong momentum and rising market interest” in the token, according to Reid, may put it in position for a later breakout. 

The technicals are quoted as indicating that we can potentially see another thrust towards the $1.22 region should market sentiment increase.

This perspective is in line with the wider trend of increased positivity towards layer-2 scaling solutions, specifically as Ethereum users are looking for cheaper alternatives when transacting. However, while these positive indicators exist, volatility in the volumes traded in ARB continues to highlight fears among investors.

image 819Source: X

Also Read | Arbitrum Holds $0.48 Support, Poised for Explosive $0.52 Breakout

ARB Price Predictions for 2025

DigitalCoinPrice forecasts that the ARB can pass through the $1.13 mark in December 2025, possibly breaking through past thresholds to reach $2.40. The analysts on the site are of the view that the ARB will find breeding ground in the region between $1.04 to $1.13, provided the market sentiment remains upbeat.

However, Changelly’s forecast is much less ambitious. Its technical outlook places the potential trade between $0.379 and $0.438 in 2025, while the mean projected price is $0.496. For the month of August in 2025 specifically, Changelly sees very little change as the token remains at $0.496 with low volatility.

Also Read | Arbitrum (ARB) 2025 Forecast: Will the Crypto Hit $2.40 Again?

Market Opportunity
Arbitrum Logo
Arbitrum Price(ARB)
$0.2086
$0.2086$0.2086
-0.94%
USD
Arbitrum (ARB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26